252 related articles for article (PubMed ID: 26284423)
1. Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical Translation.
Prasanna PG; Narayanan D; Hallett K; Bernhard EJ; Ahmed MM; Evans G; Vikram B; Weingarten M; Coleman CN
Radiat Res; 2015 Sep; 184(3):235-48. PubMed ID: 26284423
[TBL] [Abstract][Full Text] [Related]
2. Decreasing the Toxicity of Radiation Therapy: Radioprotectors and Radiomitigators Being Developed by the National Cancer Institute Through Small Business Innovation Research Contracts.
Zakeri K; Narayanan D; Vikram B; Evans G; Coleman CN; Prasanna PGS
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):188-196. PubMed ID: 30583040
[TBL] [Abstract][Full Text] [Related]
3. Development of Novel Radiosensitizers through the National Cancer Institute's Small Business Innovation Research Program.
Zakeri K; Narayanan D; Prasanna PGS; Vikram B; Buchsbaum JC
Radiat Res; 2020 May; 193(5):425-434. PubMed ID: 32216707
[TBL] [Abstract][Full Text] [Related]
4. Advancing Targeted Radionuclide Therapy Through the National Cancer Institute's Small Business Innovation Research Pathway.
Zakeri K; Narayanan D; Evans G; Prasanna P; Buchsbaum JC; Vikram B; Capala J
J Nucl Med; 2019 Jan; 60(1):41-49. PubMed ID: 30030338
[TBL] [Abstract][Full Text] [Related]
5. Investor initiatives program: Public-private partnerships to expedite commercialization for NCI-funded small business entrepreneurs.
Connors B; Lou XJ; Subedee A; Zhang K; Weingarten M; Narayanan D
Clin Transl Sci; 2021 Nov; 14(6):2124-2131. PubMed ID: 34387931
[TBL] [Abstract][Full Text] [Related]
6. CARE program: NCI and FDA interagency collaborations to support oncology small business entrepreneurs.
Pond MA; Narayanan D; Zhang K; Fau D; Summers J; Carranza D; Weingarten M
Clin Transl Sci; 2023 Mar; 16(3):412-421. PubMed ID: 36601678
[TBL] [Abstract][Full Text] [Related]
7. Creative partnerships for funding nursing research.
McCann JJ; Hills EB; Zauszniewski JA; Smith CE; Farran CJ; Wilkie DJ
West J Nurs Res; 2011 Feb; 33(1):79-105. PubMed ID: 20719996
[TBL] [Abstract][Full Text] [Related]
8. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
9. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.
Singh VK; Garcia M; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406
[TBL] [Abstract][Full Text] [Related]
10. Using database linkages to measure innovation, commercialization, and survival of small businesses.
Onken J; Miklos AC; Dorsey TF; Aragon R; Calcagno AM
Eval Program Plann; 2019 Dec; 77():101710. PubMed ID: 31518846
[TBL] [Abstract][Full Text] [Related]
11. Normal tissue protection for improving radiotherapy: Where are the Gaps?
Prasanna PG; Stone HB; Wong RS; Capala J; Bernhard EJ; Vikram B; Coleman CN
Transl Cancer Res; 2012 Jun; 1(1):35-48. PubMed ID: 22866245
[TBL] [Abstract][Full Text] [Related]
12. National Cancer Institute support for targeted alpha-emitter therapy.
Hong JA; Brechbiel M; Buchsbaum J; Canaria CA; Coleman CN; Escorcia FE; Espey M; Kunos C; Lin F; Narayanan D; Capala J
Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):64-72. PubMed ID: 34378064
[TBL] [Abstract][Full Text] [Related]
13. BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure.
Singh VK; Seed TM
Expert Opin Investig Drugs; 2020 May; 29(5):429-441. PubMed ID: 32450051
[TBL] [Abstract][Full Text] [Related]
14. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.
Singh VK; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):851-869. PubMed ID: 28650707
[TBL] [Abstract][Full Text] [Related]
15. The price of progress: Funding and financing Alzheimer's disease drug development.
Cummings J; Reiber C; Kumar P
Alzheimers Dement (N Y); 2018; 4():330-343. PubMed ID: 30175227
[TBL] [Abstract][Full Text] [Related]
16. Radiation Biomarkers: Can Small Businesses Drive Accurate Radiation Precision Medicine?
Prasanna PGS; Narayanan D; Zhang K; Rahbar A; Coleman CN; Vikram B
Radiat Res; 2020 Mar; 193(3):199-208. PubMed ID: 31910120
[TBL] [Abstract][Full Text] [Related]
17. Appraisal of mechanisms of radioprotection and therapeutic approaches of radiation countermeasures.
Mishra KN; Moftah BA; Alsbeih GA
Biomed Pharmacother; 2018 Oct; 106():610-617. PubMed ID: 29990850
[TBL] [Abstract][Full Text] [Related]
18. The NIAID/RNCP Biodosimetry Program: An Overview.
Satyamitra MM; Cassatt DR; Molinar-Inglis O; Rios CI; Taliaferro LP; Winters TA; DiCarlo AL
Cytogenet Genome Res; 2023; 163(3-4):89-102. PubMed ID: 37742625
[TBL] [Abstract][Full Text] [Related]
19. Twenty five years of the National Academy of Medical Sciences of Ukraine - progress and priorities for future of radiation medicine and biology.
Bazyka D
Probl Radiac Med Radiobiol; 2017 Dec; 22():10-14. PubMed ID: 29286493
[TBL] [Abstract][Full Text] [Related]
20. Radioprotection and Radiomitigation: From the Bench to Clinical Practice.
Obrador E; Salvador R; Villaescusa JI; Soriano JM; Estrela JM; Montoro A
Biomedicines; 2020 Oct; 8(11):. PubMed ID: 33142986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
